A Comparison of the Safety, Tolerability, and Immunogenicity of V205C Manufactured From the 2003 Measles Stock Seed With Recombinant Human Albumin (rHA) Versus Currently Licensed V205C Manufactured From the 1967 Measles Stock Seed With Human Serum Albumin (HSA) in Healthy Children 12 to 18 Months of Age.
Phase of Trial: Phase II
Latest Information Update: 18 Mar 2017
At a glance
- Drugs Measles mumps and rubella virus vaccine (Primary)
- Indications Measles; Mumps; Rubella
- Focus Adverse reactions
- 14 May 2008 Status changed from in progress to completed, reported by ClinicalTrials.gov.
- 15 Oct 2005 New trial record.